The "Prescription Drug Sales Representative Disclosure Act" aims to regulate the practice of drug sales representatives in order to control prescription drug costs. The bill requires pharmaceutical manufacturers to provide a list of their sales representatives to the Department of Business Regulation, which will then make this information available to healthcare providers, pharmacies, and medical facilities. Sales representatives will also be required to submit an annual report detailing any compensation or gifts provided to healthcare providers and the prescription drugs for which they provided free samples. The department will analyze this information and compile an annual report on the activities of pharmaceutical sales representatives. The bill establishes fees and penalties, including an annual fee for manufacturers and civil penalties for failure to comply with the disclosure requirements. The bill will take effect on January 1, 2025.